When COVID-19 exacerbates inequities: The path forward for generating wellbeing

None

Building a global psychological science through research in the Pacific Island nation of Fiji: a systematic review of the literature

There is increasing globalisation of psychological science through cross-cultural research, international conferences, and funding initiatives. However, it is important to understand the nature of this globalisation in a more nuanced way and for research to include both etic (universal comparisons) and emic (distinctive cultural understanding) approaches and to incorporate the needs and expertise of the Indigenous populations being studied. The present systematic review aimed to identify the psychological research undertaken in the culturally diverse Pacific Island Country of Fiji and explore how this has added to the general knowledge base in psychological science. Furthermore, the review aimed to use the Fiji research literature to evaluate the extent of globalisation in psychology from an etic, emic and Indigenous psychology perspective. A total of 131 peer-reviewed publications were identified on electronic databases of which 80% reported primary research studies in some form. The literature suggests a growing interest in Pacific-inclusive research that has already added substantially to psychological understanding in many core areas. However, the literature continues to be dominated by etic, cross cultural studies driven by western research interests and universal measures. The discussion suggests more needs to be done to incorporate emic approaches and Indigenous methods as well as consider applied themes and research questions that would better serve the local communities alongside scientific knowledge

Highlighting strengths in response to discrimination: Developing and testing an allyship positive psychology intervention

Allyship is gaining popularity as a tool to combat discrimination. We developed and tested a novel allyship positive psychology intervention (PPI). Importantly, we examined observers’ perceptions of intervention effectiveness given that observers represent the majority in many settings. Study 1 (N = 787) tested an intervention that highlighted a female employee’s identity-related strengths following a discrimination episode. Compared to communicating an organization’s diversity policy or confronting the transgressor, highlighting the target’s identity-related strengths was rated higher in terms of inclusion and vitality engendered in the target. Mediation analyses indicated that highlighting strengths was perceived as boosting the target’s vitality by signaling the ally’s sincerity and prompting inclusion. In Study 2 (N = 802), amongst various types of identity-related strengths, highlighting the target’s psychological and intellectual capital was as effective as highlighting all types of identity-related strengths combined, due to perceived sincerity. Thus, this research offers a quick, actionable and non-confrontational allyship PPI.&nbsp

Scaling the heights of positive psychology: A systematic review of measurement scales

The volume of empirical research on positive psychology topics has grown substantially over the past two decades.  This review examines how constructs in positive psychology have been operationalized, measured, validated, cited, and applied to build the science. Based on an archive of 972 empirical articles linked to positive psychology, this review found that 762 articles used at least one measurement scale; 312 measures were created or adapted.  Findings reveal a wide range of scales being used to measure a variety of constructs, including scales on both life-enhancing and life-depleting constructs.  Key characteristics such as journals, constructs, and scale development and validation information are discussed.  There are some reliability analyses and validations occurring within the field, but the creation of new measures far outpaces the validation of existing measures.  Weaknesses such as multiple operationalizations may be rooted in inadequate discourse and synthesis.  We call for further cross-pollination for a more scientifically robust scholarship in positive psychology

Positive Psychology Research in the Middle East and North Africa

Since the original call by Seligman and Csikszentmihalyi (2000) for a new science of happiness, excellence, and optimal human functioning, there has been considerable momentum in the research in positive psychology (see Donaldson, Dollwet, & Rao, 2014). A systematic review of the literature explicitly linked to the positive psychology movement assessed the extent of authorship, empirical and theoretical publications, and engagement of local samples in the indigenous research emerging from the Middle Eastern and North African regions. An in-depth review of these articles (n = 53) was conducted to examine the trends in publication, author locations, sample locations, key topics, research approaches and findings from exemplary articles that attend to key issues. Highlights from cross-national comparisons, cross-cultural validations and replications, research on positive constructs, and research on issues particular to the Middle East and North Africa are reviewed. Finally, unique trends of the research emerging from the Middle Eastern and North African regions are discussed and future directions for growth are explored

Le Forum, Vol. 44 #4

https://digitalcommons.library.umaine.edu/francoamericain_forum/1106/thumbnail.jp

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years